Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.34 (
lipoprotein lipase
)
7,025
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lipoprotein lipase is bound to heparin-like molecules at the surface of capillary endothelial cells. For maximal activity, the enzyme requires
apolipoprotein C-II
, a protein constituent of triacylglycerol-rich lipoproteins. In this report, the interactions of
apolipoprotein C-II
, heparin and sonicated vesicles of dipalmitoylphosphatidylcholine with purified bovine milk
lipoprotein lipase
were studied by gel filtration on Bio-Gel A5m. In the presence of vesicles of dipalmitoylphosphatidylcholine (1 mg),
lipoprotein lipase
(25 micrograms) associated with phospholipids even in the absence of
apolipoprotein C-II
. With limited phospholipid (40 micrograms), the amount of enzyme which associated with lipid decreased in the presence of
apolipoprotein C-II
(20 micrograms). Human plasma apolipoprotein C-III, another protein constituent of triacylglycerol-rich lipoproteins, also caused a decrease in the amount of enzyme associated with phospholipid. These results suggest that
apolipoprotein C-II
does not increase the activity of the enzyme by facilitating its interaction with a lipid interface. In the absence of lipid,
lipoprotein lipase
and
apolipoprotein C-II
(molar ratio, 1 : 1) eluted from Bio-Gel A5m as two separate components. The interaction of heparin with
lipoprotein lipase
was studied using a specific [3H]heparin, which was isolated by affinity chromatography on immobilized
lipoprotein lipase
; the [3H]heparin eluted with 0.6 M NaCl. Specific [3H]heparin coeluted with
lipoprotein lipase
when the enzyme was associated with phospholipid; the [3H]heparin was released from the enzyme by 0.75 M NaCl.
...
PMID:Interaction of lipoprotein lipase with phospholipid vesicles. Role of apolipoprotein C-II and heparin. 689 27
Human peripheral blood monocytes and rabbit alveolar macrophages secreted
lipoprotein lipase
during culture. Within hours after plating,
lipoprotein lipase
had accumulated in the culture medium of monocytes, and the rate of accumulation increased with time in culture. The initial rate of secretion of
lipoprotein lipase
by alveolar macrophages was higher than in monocytes but decreased after 8--10 hr to values similar to those expressed by monocytes cultured for the same length of time. The enzyme was characterized as
lipoprotein lipase
(
triacylglycero-protein acylhydrolase
,
EC 3.1.1.34
) on the basis of pH optimum (7.8--8.2 for monocytes, 8.1 for alveolar macrophages), dependence on
apolipoprotein C-II
for activity, inhibition by 0.3--0.5 M sodium chloride and protamine sulfate, and retention of a heparin-Sepharose gel. The expression of
lipoprotein lipase
secretion by human monocytes may have important implications with respect to the development of foam cells in the arterial wall during atherogenesis.
...
PMID:Lipoprotein lipase secretion by human monocytes and rabbit alveolar macrophages in culture. 695 Dec 2
1. Lipoprotein lipase was separated from normal human post-heparin plasma by affinity chromatography and assayed with a 14C-labelled triolein emulsion. No enzyme activity was detected unless whole serum was included in the assay as a source of cofactor,
apolipoprotein C-II
. 2. After a 10 h fast, serum obtained from 46 normal subjects, eight patients with hypertriglyceridaemia but normal renal function, patients with chronic renal failure (24 undialysed, 20 haemodialysed) and 14 recipients of renal allografts, was added to incubation medium for the assay of
lipoprotein lipase
to determine the maximum activation of the enzyme. 3. When serum was obtained from normal subjects, maximum activation of the enzyme correlated positively with the concentration of triacylglycerol in the sample. Neither sex nor age had a significant effect on the maximum activation achieved by serum from control subjects. 4. The maximum
lipoprotein lipase
-activating capacity of serum from uraemic and transplant patients was significantly reduced when compared with serum from healthy controls or from the non-uraemic hypertriglyceridaemic patients. 5. Maximum enzyme activation correlated positively with high-density lipoprotein cholesterol in serum from undialysed patients, but did not correlate positively with total serum triacylglycerols in any of the patient groups. Only in transplant recipients was there a significant inverse relationship between serum creatinine concentrations and maximum enzyme activation. 6. Although
lipoprotein lipase
activation was impaired in uraemic subjects and renal transplant recipients, this appeared to be due more to the presence of an inhibitor than to cofactor deficiency.
...
PMID:Impaired lipoprotein lipase activation by uraemic and post-transplant sera. 701 1
1. A variant very-low-density lipoprotein was associated with severe hypertriglyceridaemia. Urea-polyacrylamide gel electrophoresis of the tetramethylurea-soluble apolipoproteins of these very-low-density lipoproteins (VLDL) showed that the
apolipoprotein C-II
content was less than 10% of that in VLDL from hypertriglyceridaemic (3-120 mmol/l) controls. 2. VLDL were incubated with bovine milk
lipoprotein lipase
(
LPL
) and a 9,10-3H-labelled triglyceride emulsion. The VLDL deficient in
apolipoprotein C-II
were a poor activator of
LPL
, compared with the effect of VLDL with normal content of
apolipoprotein C-II
obtained from either normal or hypertriglyceridaemic sera. 3. The efficacies of various VLDL as substrates fo activated
LPL
were examined. Apolipoprotein C-II-deficient VLDL were a poor substrate for the activated enzyme compared with normal or hypertriglyceridaemic VLDL, and compared wtih an artificial triglyceride emulsion. 4. The abnormal VLDL were obtained from a subject with an IgG3 lambda myeloma protein. Intravenous infusion of normal plasma containing
apolipoprotein C-II
was followed by rapid, complete, but short-lived (5-10 days) clearance of serum triglyceride. The effect was observed on three occasions until treatment of the myeloma was effective. 5. The monoclonal protein behaved as a cryoglobulin, and formed large particle complexes with triglyceride-rich lipoproteins, especially at temperatures below 37 degrees C. The
apolipoprotein C-II
deficiency, and consequent hypertriglyceridaemia, may be secondary to an autoantibody directed against
apolipoprotein C-II
. VLDL from relatives with hypertriglyceridaemia, but without myeloma, had normal apolipoprotein content, activated
LPL
, and were efficient substrates for the enzyme.
...
PMID:Studies of a variant very-low-density lipoprotein with an acquired deficiency of apolipoprotein C-II. 705 35
The catalytic mechanism of triacylglycerol hydrolysis by
lipoprotein lipase
was studied. We found
lipoprotein lipase
to be inhibited by benzene boronic acid, with an apparent Ki of 8.9 micro M at pH 7.4. This indicates the presence of serine and histidine in the active site of the enzyme. Inhibition of
lipoprotein lipase
by benzene boronic acid is likely to be due to the formation of an inhibitor-enzyme complex having analogous bonding to the active site histidine and serine as the transition-state complex which precedes the formation of an obligatory acyl-enzyme intermediate. The presence of
apolipoprotein C-II
, the apolipoprotein activator of
lipoprotein lipase
, partly reverses the inhibition of
lipoprotein lipase
by benzene boronic acid. This reversal by
apolipoprotein C-II
has a distinct pH optimum in the range of 8-9.
...
PMID:Inhibition of lipoprotein lipase by benzene boronic acid. Effect of apolipoprotein C-II. 710 74
The composition of apolipoprotein C of the very low density lipoproteins (VLDL) was examined in 23 treated Type 2 (non-insulin-dependent) diabetic patients, who had elevated VLDL concentrations. Apolipoprotein C was separated by isoelectric focussing into
apolipoprotein C-II
which is known as the specific activator of
lipoprotein lipase
, and three apolipoprotein C-III fragments. A regulatory role has been ascribed to the ratio of
apolipoprotein C-II
to apolipoprotein C-III in the removal of plasma triglycerides. In our diabetic group, the composition of apolipoprotein C of the VLDL particles was not different from that of a healthy control group. In particular, the above apolipoprotein ratio and the relative amounts of apolipoprotein C-III fragments were normal. Hypertriglyceridaemia in these diabetic subjects does not seem to be related to alterations in the apolipoprotein C composition.
...
PMID:Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia. 710 45
Interaction of purified bovine milk
lipoprotein lipase
(LpL) with sonicated vesicles of dipalmitoyl phosphatidylcholine in the gel phase is associated with an increase in the rate of the LpL-catalyzed hydrolysis of p-nitrophenyl butyrate. There is a 6-fold increase in Vmax. Apolipoprotein C-II, the activator protein for LpL, inhibits the LpL-catalyzed hydrolysis of p-nitrophenyl butyrate. With 0.5 mol % tri[14C]oleoylglycerol present in the dipalmitoyl phosphatidylcholine vesicles and in the presence of 20 mM Ca2+, the rate of p-nitrophenyl butyrate hydrolysis is decreased reciprocally compared to trioleoylglycerol hydrolysis and is dependent on
apolipoprotein C-II
. These results suggest that
apolipoprotein C-II
enhances the activity of LpL by increasing the affinity of the active site of LpL for triacylglycerol.
...
PMID:Reciprocal effect of apolipoprotein C-II on the lipoprotein lipase-catalyzed hydrolysis of p-nitrophenyl butyrate and trioleoylglycerol. 710
The relation between pH and activity for
lipoprotein lipase
against emulsions of long-chain triacylglycerols has previously been studied in several laboratories and found to be a bell-shaped curve with optimum activity between pH 8 and 9. In contrast, using short-chain triacylglycerols or monoacylglycerols as substrates we had found that the activity rises continuously with pH to at least pH 10.5. This suggested that some factor other than the active site mechanism limited the activity at high pH in traditional assay systems. We, therefore, reinvestigated the activity against long-chain triacylglycerols under conditions where binding of the enzyme to the emulsion droplets and enzyme stability was not limiting. Under these conditions the activity continued to rise from pH 8 to pH 10, and the degree of stimulation by
apolipoprotein C-II
was found to be the same over the whole range studied (pH 6.5-10.5).
...
PMID:On the pH dependency of lipoprotein lipase activity. 711 43
Acetone powder extracts prepared from cultured pig aortic smooth muscle cells and the culture medium from these cells (particularly when incubated with heparin) were shown to contain a lipolytic enzyme which was identified as
lipoprotein lipase
by the following criteria: 1) stimulation by
apolipoprotein C-II
; 2) an optimal activity at approximately pH 8.0; 3) inhibition by NaCl, and 4) binding to a heparin-Sepharose affinity column. In addition, we found that cultured arterial smooth muscle cells from guinea pig and rabbit secreted a similar lipase into the culture medium. In contrast, studies using cultured bovine aortic endothelial cells yielded no evidence for either the synthesis or secretion of
lipoprotein lipase
by these cells. The production of
lipoprotein lipase
by the smooth muscle cells of the artery may play a role in the process of atherogenesis.
...
PMID:Lipoprotein lipase in cultured pig aortic smooth muscle cells. 712 36
Lipoprotein and apolipoprotein concentrations were determined in 11 homozygous and 9 heterozygous subjects for familial
apolipoprotein C-II
(Apo C-II) deficiency. Apo C-II was not detectable in the homozygotes, with the exception of 1 subject who possessed immunochemically detectable quantities in one of two samples. Apolipoproteins C-III (Apo C-III) and E (Apo E) were elevated 2-3-fold in 9 of 11 homozygotes. Apo C-III, but not Apo E, correlated with triglyceride levels (1500-4100 mg/dl). However, both Apo C-III and Apo E correlated with the cholesterol levels and one another. Apolipoproteins A-I (Apo A-I), A-II (Apo A-II) and B (Apo B) were reduced to approximately 50-60% of normal values in association with very low levels of cholesterol in high density (HDL; 11 +/- 2 mg/dl) and low density (LDL; 19 +/- 6 mg/dl) lipoproteins in the homozygous subjects. These alterations were associated with a marked decrease in the proportion of plasma Apo C-III associated with HDL. The levels of apolipoprotein D (Apo D) were within the normal range. Nine obligate heterozygotes had Apo C-II concentrations (mean 1.8 +/- 0.5 mg/dl; range 1.2-2.7 mg/dl) which were approximately 40-50% of normal values (mean 2.9 +/- 0.9 mg/dl; range 1.7-5.6 mg/dl). The reduction in absolute amounts of Apo C-II was also reflected in a reduction of the ratio Apo C-II/Apo C-III in very low density lipoproteins (VLDL) and in a reduction in the ability of the sera to activate skim milk
lipoprotein lipase
. The concentrations of Apo A-II, Apo B, Apo C-III and Apo E were normal. Apo A-I concentrations were normal or slightly low in association with slightly reduced concentrations of HDL cholesterol and a low proportion of plasma Apo C-III in HDL in relation to LDL and VLDL in some heterozygotes. It is concluded that the marked alterations in the apolipoprotein levels in homozygous subjects are primarily a reflection of the deficiency of Apo C-II which results in severe hypertriglyceridemia. In heterozygotes, the partial deficiency of Apo C-II appears to result in a minor disturbance of the clearance of the triglycerides and Apo C-III rich particles but no marked changes in the concentrations of total lipids, lipoproteins and apolipoproteins in fasting plasma.
...
PMID:Apolipoprotein and lipoprotein concentrations in familial apolipoprotein C-II deficiency. 713 21
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>